Effects of Growth Hormone and Pioglitazone in Viscerally Obese Adults with Impaired Glucose Tolerance: A Factorial Clinical Trial

OBJECTIVE: Recombinant human growth hormone (GH) and pioglitazone (PIO) in abdominally obese adults with impaired glucose tolerance were evaluated under the hypothesis that the combination attenuates GH-induced increases in glucose concentrations, reduces visceral adipose tissue (VAT), and improves...

Descripción completa

Detalles Bibliográficos
Autores principales: Attallah, Hamdee, Friedlander, Anne L, Nino-Murcia, Matilde, Hoffman, Andrew R
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2007
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1865086/
https://www.ncbi.nlm.nih.gov/pubmed/17479164
http://dx.doi.org/10.1371/journal.pctr.0020021

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1865086/
https://www.ncbi.nlm.nih.gov/pubmed/17479164
http://dx.doi.org/10.1371/journal.pctr.0020021

Ejemplares similares